Blood Product Development

IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. With a mission to accelerate innovation for a healthier world and a vision to power smarter healthcare for everyone, everywhere, IQVIA leverages unparalleled data, transformative technology, and deep healthcare expertise to drive better patient outcomes. Operating in over 100 countries with approximately 88,000 employees, IQVIA supports pharmaceutical, biotech, medtech, public health, and government organizations with a comprehensive portfolio of services and solutions. The company is recognized for its Connected Intelligence™, healthcare-grade AI, and commitment to sustainability, innovation, and evidence-based insights that shape the future of healthcare globally. IQVIA is also dedicated to reducing health inequities and driving sustainable change through innovation, collaboration, and data-driven solutions, partnering with organizations worldwide to address complex healthcare challenges.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.

Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. The company focuses on purpose-driven innovation to empower healthcare professionals and enhance patient outcomes across various medical fields.

Qidni Labs is a NATO DIANA company recognized by Fast Company as a 2025 World Changing Idea. The company has developed a portable, nearly waterless hemodialysis system that will make treatment accessible for over 10 million patients every year.

VirTech Bio is an early-stage biotechnology company based in Natick, Massachusetts, focused on developing a human-derived hemoglobin-based oxygen carrier (HBOC) for use as a temporary blood substitute in trauma and transplantation. The company leverages expertise in hemoglobin polymerization to address critical needs in emergency medicine and organ preservation, with a pipeline also targeting veterinary and research applications. Process innovations allow scalable and contract-based manufacturing, supported by significant non-dilutive funding from the US Department of Defense and private investment.

GreenLifeTech has developed a safe, non-chemical means of removing oxygen from within a closed container operated at atmospheric pressure (no vacuum). This inert environment allows for the extending the shelf life of perishable material. Initially, the focus was on fresh produce which can have its shelf life extended by up to 3 - 5x, thereby reducing food waste and promoting healthier living. An EPA SBIR phase II contract has already been awarded for implementation of the technology in consumer refrigerators. In addition, the technology is applicable to preserving transfusion blood. NIH and US Army studies have already shown that storing blood in an anaerobic environment improves the quality and extends the shelf life of blood. The GreenLifeTech now makes this cost effective and applicable in the field.

Anavatos Bio is an early-stage biotechnology start-up based in Seattle, Washington, dedicated to revolutionizing biologics manufacturing. The company is driven by a team of experienced scientists, engineers, and entrepreneurs passionate about increasing access to protein therapeutics. Their mission is to enable faster, more efficient, and cost-effective production of biologics at smaller scales, supporting early-phase research and advancing a new medical paradigm that delivers greater value to patients.

Altra Inc. is at the forefront of revolutionizing infusion therapy with its innovative Altra Infusion System. The company is dedicated to addressing the critical challenges in the infusion industry, such as mechanical failures, flow issues, and false alarms, which contribute to a significant portion of medication errors and adverse drug events. Altra's mission is to ensure patient safety and improve healthcare delivery through advanced technology solutions.

MK Strategy Group is a certified Service-Disabled Veteran-Owned Small Business (SDVOSB) and a leading government contractor specializing in innovative healthcare solutions for military, government, and commercial sectors. With over two decades of experience, the company excels in medical procurement and facility development. MK Strategy Group bridges the gap between medical technology providers and government agencies, offering tailored, turnkey solutions that accelerate success in the government market. Their approach combines military precision, deep industry expertise, and a commitment to quality, innovation, and financial stability—enabling them to manage large-scale, complex projects with efficiency and reliability.

SanaHeal is dedicated to developing next-generation bioadhesive technologies inspired by nature to solve significant challenges in healthcare. Their innovative solutions are designed to adhere to wet and uneven surfaces, providing rapid and robust adhesion for various medical applications.

Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.

The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.

Harmac is a global contract design and manufacturing organization specializing in single-use medical devices. With over four decades of experience, Harmac provides comprehensive services including product design and development, advanced manufacturing, automation, value engineering, quality assurance, and packaging and sterilization. The company is known for its operational excellence, regulatory compliance, and commitment to sustainability and community engagement. Harmac operates facilities across the United States, Ireland, and Mexico, supporting customers worldwide and across a range of clinical applications. ISO 13485 Certified and FDA Registered.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

DLH delivers improved health and national security readiness solutions for federal programs through science research and development, systems engineering and integration, and digital transformation. With over 3,200 employees, DLH is committed to solving complex problems faced by civilian and military customers, leveraging advanced technologies and methodologies to enhance health outcomes and operational readiness.

Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Orbis Diagnostics is pioneering the development of a next-generation Point-of-Care Diagnostics platform. Their mission is to deliver clinically-accurate blood test results from just a single fingerstick, reimagining the future of blood diagnostics for greater accessibility and efficiency.

RBT Resources is a service-disabled veteran-owned medical device company focused on rapidly improving damage-control resuscitation and blood delivery in austere, prehospital, and mass-casualty environments. The company is developing a next-generation rapid blood transfusion platform that leverages a compact, reusable pump and mission-configurable disposables to enable faster, more controlled administration of whole blood and blood products at the point of injury. Founded by former U.S. Special Operations Forces operators, RBT Resources is dedicated to closing critical medical capability gaps observed in combat through user-driven design and close collaboration with military medical teams. ​

NuShores Biosciences LLC, founded in 2014, is dedicated to commercializing patented bone and tissue regeneration technologies developed at the University of Arkansas at Little Rock. The company aims to improve the quality of life for individuals with severe tissue regeneration needs through innovative solutions like the NuCress™ bone scaffold technology, which is designed to promote healing in large segmental bone defects.

Vivosang Inc is an investigational stage biotechnology company focused on developing pegylated human hemoglobin products to enhance oxygen delivery in medical applications, particularly in traumatic hemorrhagic injuries. Their lead product, VS-101, aims to provide targeted oxygen delivery to tissues in need, addressing significant medical needs in emergency and surgical settings.

Ease Healthcare (a registered DBA of MPS Medical, Inc.) is committed to advancing next-generation military medicine by accelerating access to clinically validated diagnostic tools, monitoring devices, and health and wellness technologies. As a trusted commercialization partner and distributor, the company empowers providers, organizations, and individuals with advanced solutions that support early detection, timely intervention, and improved health outcomes in both civilian and military settings. With a mission to make cutting-edge science and technology accessible to all, Ease Healthcare focuses on addressing critical health challenges such as 02 delivery, cancer, and cardiovascular disease —areas that directly impact force readiness and resilience. The company’s vision is to break barriers in healthcare by delivering innovative medical solutions that are affordable, accessible, and simple to use, regardless of economic or geographic limitations. In addition to bringing transformative technologies to market, Ease Healthcare provides turnkey services for medical device manufacturing and distribution, guiding partners from product development through regulatory compliance and successful deployment. By combining technical expertise with a dedication to accessibility, Ease Healthcare supports the Department of Defense’s priorities in preparing and protecting service members with next-generation healthcare solutions.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

The University of Cincinnati Office of Research is a premier R1 urban research institution dedicated to advancing transformative knowledge and disruptive discoveries that address real-world challenges. Guided by its Research2030 strategic plan, the Office fosters interdisciplinary collaboration, supports innovative research initiatives, and connects industry, government, and community partners with UC's thought leaders. The Office accelerates economic growth and societal impact by investing in key research strengths such as analytics, cyber, robotics, sensors, skin science, adolescence, cancer, digital humanities, infectious diseases, medical devices, neuroscience, smart cities, sustainability, urban futures, and water. With a strong commitment to transparency, compliance, and research security, the Office provides comprehensive support for faculty, students, and staff throughout the research lifecycle, ensuring excellence and integrity in all scholarly activities. Specialized programs and support offices include biosafety, animal care, research integrity, cybersecurity, human research protection, defense research initiatives, government cost compliance, and radiation safety, all designed to uphold the highest standards of ethical, safe, and innovative research. The Office also keeps the community informed and engaged through its monthly 'Findings' newsletter, highlighting impactful research, partnerships, and opportunities.

Thornhill Medical specializes in advanced medical technologies for critical care, anesthesia, respiratory therapy, and vascular diagnostics. Their core offerings address clinical needs in austere, emergency, battlefield, and transport environments, enabling mobile and integrated life support, portable anesthesia, and precise non-invasive control and measurement of blood gases. With significant expertise in both product engineering and translational clinical research, the company supports deployments worldwide, collaborates with military and civilian partners, and contributes to innovation in healthcare delivery and device interoperability.

Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage. In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to address any increase in demand, particularly mass casualty events, military conflicts or significant hemorrhage situations such as post-partum hemorrhage and traumatic injury. This means: 1) Platelet rationing occurs across the system. 2) Nearly 400,000 platelet units a year expire before they can get to a patient in need. 3) Ten million Americans on anti-platelet or anticoagulant medications face greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care.

Profusa, Inc. is a pioneering digital health company based in the San Francisco Bay Area, dedicated to making the body’s chemistry easily accessible to improve health and wellness. Profusa develops tissue-integrating biosensors for continuous, real-time monitoring of body chemistries, empowering individuals and clinicians with actionable, medical-grade data to transform personal health management and disease prevention. Their unique bioengineering approach overcomes the foreign body response, enabling long-term, in-body monitoring through tiny, flexible biosensors that become one with the body. Profusa’s technology platform supports both consumer and medical applications, with a vision to revolutionize personalized medicine and digital health. The company is supported by significant grant funding from agencies such as DARPA and NIH, and collaborates with leading academic, hospital, and industry partners worldwide.

Machina Medical is dedicated to revolutionizing wound and hemostatic care technology. We aim to save lives and limbs by providing innovative solutions for controlling blood loss and wound care management. Our flagship product, MFUSE, is designed to address the critical need for rapid and effective bleeding control in combat, trauma, and surgical settings. Our breakthrough adhesive technology enables rapid, robust, and on-demand detachable adhesion to bleeding wounds that fundamentally addresses the limitations of the conventional hemostatic mechanism.

Blood Centers of America (BCA) is the largest blood supply network in the United States, comprising over 60 independent community blood centers that collectively distribute approximately 50% of the nation's blood supply. BCA supports member organizations through supply chain solutions, donor recruitment, advocacy, disaster response, and purchasing power. In addition to providing whole blood, red blood cells, platelets, plasma, cells, and tissues for therapeutic, diagnostic, research, and advanced therapy applications, BCA and its network are engaged in the development and delivery of advanced therapies including cell and gene therapy starting materials, processing, and manufacturing. BCA actively mobilizes resources in response to national emergencies, pandemics, and technological advances in donor experience and biotherapeutics.

Solventum is a healthcare company dedicated to enabling better, smarter, and safer healthcare solutions. With a legacy of innovation, Solventum focuses on improving patient outcomes through advanced medical technologies, oral care solutions, health information technology, and purification and filtration systems.

VETRUN LLC is intentionally structured as a lean, project-focused organization designed to deliver complex, regulated medical products with speed, accountability, and cost efficiency. Rather than maintaining large internal departments for legal, regulatory, testing, manufacturing, and specialized engineering functions, VETRUN utilizes a distributed execution model, contracting with best-in-class service providers as required by each program. VETRUN works exclusively on one project at a time, enabling full leadership focus, rapid decision-making, and disciplined execution without competing internal priorities. This model allows VETRUN to assemble a tailored team of subject matter experts for each program, including legal counsel, FDA regulatory consultants, accredited testing laboratories, industry experts, contract manufacturers, and design and development partners. These relationships are not ad hoc. VETRUN has curated a robust network of U.S.-based (“Made in USA”) companies over more than 20 years, selecting partners with demonstrated experience in FDA-regulated medical devices, government programs, and high-reliability manufacturing. This long-standing network enables VETRUN to rapidly mobilize proven resources, scale capabilities as needed, and replace or augment services without disruption. By avoiding fixed overhead associated with large permanent staff and facilities, VETRUN maintains low indirect costs while preserving access to deep technical and regulatory expertise. This structure enhances flexibility, reduces financial risk, and allows resources to be applied directly to execution and milestone achievement rather than administrative burden. This execution model results in a company that is fast-moving, adaptable, and highly responsive, well-suited for time-sensitive programs requiring regulatory rigor, domestic manufacturing, and close coordination with Government stakeholders. VETRUN’s role is to serve as the integrator and accountable authority, ensuring that all partners operate cohesively toward a common objective while maintaining schedule discipline, quality compliance, and mission focus.

Kromek Group plc develops advanced detection technologies for radiological, nuclear, and biological threats using Cadmium Zinc Telluride (CZT) solid-state detectors. The company offers manufacturing and R&D for high-resolution gamma and neutron detectors, networked and wearable monitoring devices, and automated pathogen detection platforms. Its solutions serve the civil nuclear, medical, environmental, defense, and public health sectors worldwide, enhancing safety, operational efficiency, and health security.

CellBios is a biotechnology company specializing in the design, development, and manufacturing of single-use bioprocessing and medical device solutions for healthcare, biotechnology, and regenerative medicine sectors. The company operates GMP and ISO-certified cleanroom facilities, offering a comprehensive portfolio of cryopreservation products, bioreactors, fluid management systems, advanced packaging, and specialty devices. By leveraging expertise in extrusion, molding, assembly, sterilization, quality control, and regulatory compliance, CellBios provides customized, scalable solutions to support blood transfusion, cell and gene therapy, biologics manufacturing, and clinical workflows.

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, dedicated to providing high-quality, patient-centered care. With a history of innovation spanning nearly 150 years, Mayo Clinic is committed to transforming healthcare through research, education, and compassionate care, ensuring that the best possible treatment is available to everyone.

Draper is an independent nonprofit engineering innovation company with a legacy spanning over 90 years, dedicated to delivering transformative solutions for national security, prosperity, and global challenges. Renowned for its pioneering work in guidance, navigation, and control (GN&C) systems, Draper partners with government, industry, and academia to engineer advanced technologies in space, defense, biotechnology, and electronic systems. The company leverages multidisciplinary expertise, digital engineering, and a collaborative approach to provide field-ready prototypes, mission-critical systems, and innovative research. Draper’s mission is to ensure the nation's security and prosperity by delivering sustainable, cutting-edge solutions that address the toughest problems of today and tomorrow, while fostering an inclusive and diverse workforce. Draper also invests in the next generation of innovators through robust educational programs, including internships, co-ops, and the Draper Scholars Program, integrating academic research with real-world problem-solving.

The University City Science Center (the Science Center) is a 501(c)3 non-profit organization based in Philadelphia, PA. The Science Center catalyzes innovation to maintain the technological superiority of the American military and the strength of the American economy. The Science Center’s core activities include programming to support and train entrepreneurs, commercialize dual use technologies, expand available capital for high growth firms, and cultivate the domestic STEM talent pipeline. We empower early-stage companies to secure and manage federal funding through specialized assistance. By leveraging our government relationships, providing comprehensive proposal development, and deploying sophisticated award management, the Science Center streamlines the process for startups in accessing federal funding. By ensuring that American scientific and technological innovations are rapidly advanced and integrated into defense and dual-use applications, the Science Center strengthens the US industrial base, enhances military readiness, and safeguards national security interests. This lab-to-market pipeline is critical to maintaining technological overmatch, securing supply chain resilience, and reinforcing biosecurity infrastructure. The Science Center’s innovation acceleration initiatives can directly contribute to the Department of Defense’s modernization priorities by reducing reliance on foreign technologies, fostering high-growth industries in critical technology areas, and ensuring that STEM advancements serve as strategic assets to protect and advance US interests. Since its founding, the Science Center’s commercialization and small business programming efforts have supported more than 700 companies, leading to 29,100 jobs with an average salary of $105,000 and $7.6 billion in annual economic impact in Greater Philadelphia. Through its commercialization programs, the Science Center has supported a range of mission-critical innovations that align with DoD priorities, including warfighter readiness, medical technology advancement, and operational resilience.

Ambient Biosciences is a global leader in biostabilization, dedicated to eliminating cold chain reliance and improving global health equity through innovative biomolecule stabilization technology. Their patented Capillary-Assisted Vitrification (CAV) process enables room-temperature storage and shipping of sensitive reagents and biomolecules, offering a superior alternative to traditional lyophilization and cryopreservation. With a values-driven, diverse team of scientific experts and visionary leaders, Ambient Biosciences is committed to transforming laboratory operations, reducing costs and waste, and making life sciences more accessible and sustainable worldwide.

Micron Biomedical is a clinical-stage life science company and the leader in dissolvable microarray-based technology for needle-free delivery of vaccines and therapeutics. The company's mission is to radically expand access to treatments and vaccines, improve global health outcomes, and transform how vaccines and drugs are administered. Micron's proprietary technology enables painless, thermostable, and self-administered drug and vaccine delivery, eliminating the need for cold chain logistics and reducing infrastructure barriers. The company is recognized for its innovative approach to overcoming vaccine hesitancy and access challenges, and is rapidly advancing toward commercializing its technology for global impact. Micron partners with leading global health organizations and has secured significant funding to accelerate the development and commercialization of its needle-free solutions.

RxMP Therapeutics is dedicated to developing innovative therapies aimed at preventing and treating hemorrhage and excessive bleeding associated with trauma, surgery, or bleeding disorders. The company focuses on creating novel hemostatic agents that can effectively stop bleeding while minimizing the risk of unwanted clotting elsewhere in the body. Their lead product, RMP-402, has significant market potential and is backed by substantial funding to support its development.

InFlo Medical is pioneering the future of extracorporeal life support with the MOBYBOX - the world's first fully portable ECMO (extracorporeal membrane oxygenation) system. This breakthrough portable ECMO device weighs only 10 pounds and operates entirely on compressed gas power, delivering superior gas exchange performance in an ultra-compact, biocompatible design. The MOBYBOX portable ECLS (extracorporeal life support) technology represents a paradigm shift in emergency cardiac care, critical care transport, and point-of-care oxygenation. Unlike traditional bulky ECMO systems, our miniaturized ECMO solution enables rapid deployment in ambulances, helicopters, remote locations, and resource-limited settings where conventional extracorporeal membrane oxygenation is impossible. Key advantages of the MOBYBOX portable ECMO system include best-in-class oxygenation efficiency, reduced priming volume, lower pressure drop, enhanced patient mobility, and simplified operation - making advanced ECLS therapy accessible anywhere critical care is needed.

Aridica Corporation is dedicated to advancing immune system research and clinical applications by providing high-quality, automated immune cell isolation solutions. Their mission is to accelerate the development of diagnostics and next-generation therapeutics by simplifying and standardizing the process of immune cell separation. With a focus on automation, reliability, scalability, and sustainability, Aridica aims to empower researchers and clinicians to unlock the full potential of the immune system for improved health outcomes.

DesiCorp, Inc. is pioneering the development of thermally stable packed red blood cells, revolutionizing battlefield medicine and blood transfusion technology. Their innovative solutions enable rapid and reliable care, allowing medics to administer life-saving transfusions within minutes of injury. With advancements that allow blood to be stored for years, DesiCorp is addressing critical medical challenges in trauma care.

Cresilon is a Brooklyn-based biotech company dedicated to saving lives through innovative hemostatic solutions. Their mission is to provide safe, effective, and reliable products that stop bleeding quickly, utilizing plant-based technology to revolutionize wound care in both veterinary and human medicine.

Safi Biotherapeutics is dedicated to developing on-demand blood cell therapies tailored for individuals in need. As a commercialization partner for a Department of Defense program, the company focuses on overcoming challenges in cell therapy manufacturing, ensuring high consistency and economic viability.

Southwest Research Institute (SwRI) is a nonprofit research and development organization that provides independent, premier services to government and industry clients. Founded in 1947, SwRI is committed to advancing science and technology to benefit humanity, focusing on innovative solutions that improve human health and safety. With a diverse range of technical divisions, SwRI addresses complex challenges in various fields including mechanical engineering, materials, aerospace, automotive, biomedical, and more.

BioFactura, Inc., based in Frederick, Maryland, is a biopharmaceutical company specializing in the development and commercialization of high-value biosimilars, biodefense medical countermeasures, and novel drugs. Leveraging its proprietary StableFast™ Biomanufacturing Platform, BioFactura delivers faster, lower-cost, and superior-quality biologics. With over a decade of experience, the company has advanced life-saving medicines from research to patient care, focusing on unmet global biomedical and national biodefense needs. Its portfolio includes drugs for smallpox, Ebola, cancer, autoimmune, and infectious diseases.

HNu Photonics is a Hawai’i-based science and technology company specializing in the research, design, fabrication, and assembly of advanced photonics, optics, and instrumentation technologies. The company provides integrated solutions across biotech, defense, energy, and advanced manufacturing sectors, offering vertically-integrated services from concept development to finished products. Areas of focus include renewable energy systems, defense photonics, specialized optics, and medical imaging technologies.

ARMR Systems, Inc. is dedicated to revolutionizing trauma care by engineering simple solutions to complex challenges. The company focuses on creating hemorrhage control systems that enhance the survivability of traumatic pre-hospital injuries, especially in situations where advanced medical help is not immediately available. Their mission is to democratize access to care and empower first responders, ensuring that anyone, regardless of their location or background, can confidently respond to emergencies. ARMR Systems champions a new approach to trauma care and preparedness, aiming to replace barriers to access with systems of equity.

NTx Bio (Nature’s Toolbox, Inc.) is revolutionizing biomanufacturing by enabling on-demand, decentralized, and scalable production of high-quality RNA and proteins. Our mission is to democratize access to medicines by overcoming the bottlenecks of traditional, centralized manufacturing. Through proprietary, synthetic biology platforms like NTxscribe® (mRNA production) and NTxpress® (cell free protein production), NTx empowers researchers and companies to accelerate the development and delivery of personalized and mass-scale therapeutics, making next-generation medicine more accessible, sustainable, and efficient, while eliminating supply chain concerns by using 100% domestic inputs and production capabilities.

Sempulse is a pioneering company that empowers medical professionals with advanced non-invasive monitoring technology. Their flagship product, the Halo Vital Signs Monitor, allows for real-time tracking of multiple patients' vital signs from a single device, enhancing patient care and operational efficiency in various healthcare settings. Sempulse's mission is to improve patient outcomes through innovative technology that integrates seamlessly into existing healthcare systems.

Persist AI is a biotechnology company pioneering the use of AI-driven robotics to accelerate and transform pharmaceutical formulation development. Their mission is to deliver life-saving drugs faster, with fewer side effects, and improved patient outcomes by leveraging advanced automation, machine learning, and high-throughput experimentation. Persist AI's integrated platform addresses the bottlenecks of traditional drug formulation by combining custom robotics, computational chemistry, and proprietary AI models, enabling rapid, scalable, and cost-effective development of complex drug delivery systems such as long-acting injectables. With a global presence and a team of experts in drug delivery, automation, and machine learning, Persist AI is committed to making advanced drug delivery systems more accessible and efficient for the pharmaceutical industry worldwide. The company also demonstrates a strong commitment to data protection, privacy, and security, implementing robust technical and organizational measures in compliance with international standards.

Swaza Inc. is a biotechnology company focused on developing revolutionary oxygen nanotherapeutics. Their mission is to provide innovative solutions for respiratory distress through non-invasive nanofluid breathing aids and advanced regenerative biomaterials, leveraging their proprietary nanotechnology platform.

Cepheid is a global leader in molecular diagnostics, dedicated to improving healthcare by developing, manufacturing, and marketing automated, easy-to-use molecular systems and tests. Their mission is to provide rapid, accurate, and actionable genetic testing for a wide range of infectious diseases, oncology, and human genetics. Cepheid's flagship GeneXpert System delivers scalable, sample-to-answer PCR testing for institutions of any size, supporting both centralized and decentralized care. The company is committed to expanding access to high-quality diagnostics worldwide, supporting public health initiatives, driving innovation in molecular testing, and advancing sustainability and responsible business practices.

The Israel Innovation Authority is the central governmental body responsible for fostering and advancing Israel's innovation ecosystem. Its mission is to power innovation through investment, insight, and impactful programs, supporting high-tech entrepreneurship, deep-tech ventures, and global collaborations. The Authority provides non-dilutive funding, strategic support, and regulatory guidance to startups and established companies, ensuring Israel remains a global leader in technology and innovation. With a focus on sectors such as AI, bioconvergence, foodtech, climate tech, and more, the Authority bridges academia, industry, and international partners to address humanity's pressing challenges and drive economic growth. Israel's tech ecosystem, often called the "Startup Nation," is characterized by a culture of bold experimentation, interdisciplinary collaboration, and resilience, making it a global powerhouse for innovation. The Authority also plays a pivotal role in shaping national innovation policy, supporting R&D, and facilitating co-investment opportunities for international investors. The Authority's unique features include proactive future-readiness, risk-absorbing investment models, global market integration, and resilience in times of crisis, such as the deployment of Fast-Track bridging funds to protect startups. The Authority also operates innovation centers and manufacturing accelerators to expand high-tech opportunities geographically and demographically, and regularly identifies and supports emerging technologies with high potential impact. The Authority supports a vast portfolio of startups and scale-ups across diverse sectors, including medical engineering, software, electronics, foodtech, biotech, and more, through programs such as Tnufa, Technological Incubators, R&D grants, and international collaborations.

AvantGuard has developed a novel broad-spectrum, bio-compatible antiseptic that is proven in in vitro, ex vivo, and in vivo testing to be safe and more effective than topical antibiotics, while also effective as a liquid sterilant or disinfectant. Our compound, Avantamine, can be packaged as a heat-tolerant, long-shelf-life powder in a metal foil packet that dissolves rapidly in potable water to make either a solution or hydrogel. At a high concentration, Avantamine's non-hazardous, non-corrosive solution will sterilize medical equipment in 10 minutes and is safe enough for instruments to be removed and used without rinsing. Diluted by half, Avant24 at 0.6% concentration is (1) an antiseptic for washing wounds or treating cutaneous bacterial and fungal infections, (2) a high-level disinfectant for a variety of medical devices without corroding metals or degrading plastics, and (3) a disinfectant for surfaces in the surgical suite. At 6X further dilution, Avant24 can treat trench mouth. At another 3X dilution, Avant24 can be added to water to make it drinkable. There are an enormous number of potential uses and the only difference between them is the amount of diluent, in this case water, used to prepare the solution. Our military focus areas are (1) low resource sterilization of medial devices, (2) fungal treatment for burn wounds, and (3) a prophylactic for infection control in a self-administered Role 1 environment with the powder applied directly to a wound. Our commercial focus area is Candida auris decolonization which is not currently possible with any other antiseptic. We have definitive animal testing to show efficacy and superiority to chlorhexidine and are moving toward the clinic.

The Southwest Texas Regional Advisory Council (STRAC) is dedicated to developing, implementing, and maintaining a regional trauma and emergency healthcare system for the 22 counties in Trauma Service Area – P. STRAC aims to reduce death and disabilities related to trauma, disaster, and acute illness through well-coordinated emergency response systems, striving to be a model for emergency healthcare in the United States.

North American Rescue (NAR) is dedicated to decreasing preventable death by providing the most effective and highest quality mission critical medical products to military, federal agencies, civilian law enforcement, EMS, and pre-hospital life savers. NAR designs, develops, and tests products based on Tactical Combat Casualty Care (TCCC) guidelines, ensuring they meet the evolving needs of first responders and healthcare providers. NAR is committed to quality, with a focus on American-made products and adherence to the highest industry standards.

Macro Biologics, Inc. is dedicated to designing, patenting, and producing macro biologics, which are large molecule biologics with both physical properties and functional activities. These biologics are composed of natural building blocks, such as amino acids or carbohydrates, and are designed to degrade back into their natural components, making them environmentally friendly. The company aims to address significant global challenges, such as antibiotic resistance and pollution, by providing biologics that are safe for both people and the environment. Macro Biologics is committed to the highest standards of science, medicine, and business, with a focus on healthcare applications.

The University of Arizona Applied Research Corporation (UA-ARC) is a non-profit organization affiliated with the University of Arizona, dedicated to leveraging the university's strengths in research and education to address national security challenges. UA-ARC aims to deliver innovative solutions and foster collaborations between academia, industry, and government.

Frontier Bio creates lab-grown human tissues to reduce the worldwide organ shortage. Their first clinical product is a tissue-engineered vascular graft made from the patient's own cells.

LenioBio GmbH develops scalable eukaryotic cell-free protein expression technologies enabling rapid and flexible production of complex proteins. Its proprietary platform facilitates expression of membrane proteins, antibodies, virus-like particles, and proteins with complex post-translational modifications, supporting applications from research to biomanufacturing and vaccine development. The technology addresses key bottlenecks in traditional protein production, offering fast turnaround, batch consistency, and the potential for integration with rapid DNA template synthesis. LenioBio collaborates with leading industry partners and continually advances its platform for broad accessibility and application in life sciences.

The Institute for Biohealth Innovation (IBI) at George Mason University unites over 300 faculty and thousands of students across 34 departments to advance human health and well-being through innovative research. The IBI focuses on major health challenges, including infectious diseases, cancer, brain and behavior, and cardiovascular health, collaborating with national and international partners to implement solutions that enhance health outcomes.

Inflammasense specializes in advancing healthcare and clinical research through the integration of neural and molecular biomarkers. By leveraging continuous, real-time physiological and molecular data, the company aims to facilitate precision treatments, accelerate clinical trials, and enhance early detection and prevention of critical illnesses such as sepsis and hemodynamic compromise. Their technology platforms including the wearable VITALX-PATCH and Point of Care micro-RNA Handheld Ultra-sensitive Biomarker Sensor (HUBS) systems support clinical trials, defense, and corporate wellness sectors, with a focus on expedited objective decision-making and scalability. The company has secured $4.05 Mil in non-dilutive funding from DARPA, BARDA and the NIH, while it has now closed a total of 1.65 Mil in dilutive funding from KittyHawk Ventures (Pre-seed of $250K) and private investment of (Seed $1.5 Mil). The 2 years long Pre-Seed funding is scoped to obtain FDA 501 (k) clearance of the VITALX-PATCH and initiate FDA submissions for the HUBS device. InflammaSense is seeking $7.5 Mil investment for the clinical trials and product manufacturing to scale for DeNovo approved devices. The approved device is indicated for the first beach head use case as a companion diagnostic for individualized Sepsis therapy.

The University of Minnesota's Research and Innovation Office (RIO) serves as a central resource for conducting, managing, and sponsoring research. It aims to facilitate collaborative research that addresses complex problems and promotes innovations that improve lives. RIO oversees research compliance and administration, fostering a culture of integrity and ethical practices in research. Additionally, RIO is committed to enhancing research capacity through various funding opportunities and strategic initiatives, including the management of specialized facilities for biocontainment research.

Cayuga Biotech is dedicated to harnessing the body's innate ability to halt bleeding and heal, addressing significant unmet needs in hemorrhage control and bleeding disorders through proprietary science and innovative solutions.

SurgiBox Inc. is transforming surgical care with award-winning, patented technology designed to make safe surgery possible anytime, any place. Our flagship product, SurgiField, is an ultra-portable, battery-powered solution that enables safe, clean surgical conditions - from private clinics to the most hard-to-reach austere settings, namely disaster and conflict zones. Built on years of research and collaboration with leading clinicians, SurgiField integrates seamlessly into existing surgical workflows and meets the highest regulatory standards, including CE Mark under EU MDR, ISO 13485 compliance and approval in Japan. Pending regulatory approval in Taiwan, UAE, KSA, and Türkiye. Founded by Harvard Medical School-educated clinicians and incubated at MIT D-Lab, SurgiBox is committed to making surgery safer, more accessible, and more adaptable worldwide.

Northwestern University is a prestigious institution dedicated to fostering a diverse and inclusive environment, promoting academic excellence, and engaging in impactful research. With campuses in Evanston, Chicago, and Doha, Qatar, Northwestern emphasizes global engagement and community involvement, preparing students to tackle complex challenges through interdisciplinary collaboration and innovative thinking.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Versiti is a nonprofit, 501(c)(3) blood health organization dedicated to improving patient lives and supporting healthcare partners through blood donation, innovative research, and advanced diagnostic testing. With locations across the Midwest, Versiti is a leader in blood health innovation, organ and tissue donation, and precision medicine. The organization is committed to enhancing patient care, advancing healthcare standards, and fostering a vibrant donor community. Versiti also supports education through scholarships and is recognized for its compliance and accreditations.

Haima Therapeutics is a pre-clinical stage biopharma company focused on developing cell-inspired therapies for the treatment of bleeding and various blood-related diseases. Their lead technology, SynthoPlate, is a novel, fully-synthetic hemostatic agent designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the site of injury.

Polaroid Therapeutics is a Swiss-based biotech start-up, established in 2022 and incubated by the iconic Polaroid brand. The company is dedicated to addressing major challenges in antimicrobial therapies through cutting-edge technology and research. Its mission is to create a more human, meaningful, and healthier world by developing proprietary antimicrobial polymer technologies that reduce bioburden, improve patient outcomes, and do not trigger antimicrobial resistance (AMR). Polaroid Therapeutics focuses on advanced wound care, medical device coatings, and holistic therapeutic applications, aiming to set new standards in patient-centric care and global health.

Spectral Platforms is pioneering rapid diagnostic solutions in clinical microbiology, focusing on eliminating time-consuming steps in traditional microbiology to enable faster, more accurate detection and characterization of pathogens. Their proprietary technology leverages sensitive detection of bacterial metabolites and redox state changes, providing results in minutes rather than days. The company aims to improve patient outcomes, particularly in sepsis and infectious disease management, by delivering rapid, reliable, and actionable diagnostic information. Spectral Platforms also offers advanced microbiology services and collaborates with leading institutions and regulatory bodies to validate and deploy their innovations.

Auric Innovations develops emergency medical technologies focused on hemorrhage control, casualty monitoring, and trauma care in both civilian and military environments. The company designs and manufactures medical devices and training systems, including advanced tourniquet platforms, hemorrhage control simulators, and wearable biosensor technologies. Current development efforts include patented networked tourniquet systems capable of transmitting location and physiological data to responders, enabling real-time casualty awareness, automated alerts, and improved decision support during prehospital and battlefield care. Integrated AI models analyze sensor and operational data to assist with triage, injury assessment, and responder decision-making in time-critical environments. Auric Innovations’ technologies are designed for dual-use deployment across military medicine, emergency medical services, law enforcement, and disaster response.

Triton Genomics develops portable, field-deployable systems for automated preparation of DNA and RNA libraries used in next-generation sequencing (NGS). The company's technology is designed to function reliably in challenging field conditions and to enable rapid, user-friendly, and safe sample processing at the point of collection. Triton Genomics aims to democratize access to advanced genomic analysis for both scientists and non-scientists across diverse application areas such as public health, environmental monitoring, and forensic science.

The University of Missouri is dedicated to advancing research, innovation, and impact through a comprehensive support system for faculty, students, and staff. It aims to foster collaboration, enhance economic development, and promote entrepreneurship, while ensuring compliance with research regulations and ethical standards. The university also emphasizes the importance of interdisciplinary partnerships and provides resources to support veteran entrepreneurs through programs like the Entrepreneurship Bootcamp for Veterans.

Viscus Biologics LLC specializes in product realization from ideation to high volume production, manufacturing components, devices, and products with natural polymer and extracellular matrix materials. The company aims to fulfill patient and market needs, improve quality of life, and restore tissue to a healthy state.

Prolific Machines is pioneering the use of optogenetics and AI-driven bioprocess optimization to revolutionize biomanufacturing. Their mission is to illuminate biology’s limitless potential for a healthier tomorrow by enabling the production of next-generation therapeutics and broadening patient access to life-altering medicines. Founded in 2020, the company has developed a unique Photomolecular™ platform that uses light to precisely control cellular functions, boosting yields, improving quality, and enabling the manufacture of complex biotherapeutics. With a focus on strategic partnerships, Prolific Machines collaborates with innovators in biopharma and advanced nutrition, offering flexible, scalable solutions and in-house cell line development up to 200-liter pilot scale. The company is recognized for its commitment to safety, innovation, and a collaborative, diverse team culture.

MLM Biologics Inc. is dedicated to advancing wound care through innovative solutions like the bio-ConneKt® Wound Matrix, a collagen-based product designed for effective wound closure. The company emphasizes a mission of providing more effective and economical solutions for wound healing, aligning with the Gandhian Economic Principle of 'More for Less for Many.'

The University of Massachusetts Lowell (UML) is dedicated to providing a comprehensive educational experience that prepares students for success in their careers and lives. With over 200 degree programs and a commitment to research and community engagement, UML fosters a vibrant learning environment for its diverse student body.

RTI International is an independent nonprofit research institute dedicated to improving the human condition. With a vision to address the world's most critical problems through science-based solutions, RTI integrates expertise across social and laboratory sciences, engineering, and international development to deliver reliable data, thorough analysis, and innovative methods that inform public policy and practice.

MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.

TDA Research, Inc. is dedicated to addressing complex real-world problems through innovative research and development in chemical processes, materials, and hardware. With a focus on agility and collaboration, TDA partners with clients in defense, aerospace, energy, and chemical industries to deliver cutting-edge solutions and technologies.

Goodrich Lab at Colorado State University focuses on research for treating and preventing disease transmission, with emphasis on vaccine development and pathogen inactivation using photochemical methods. The lab conducts both fundamental and translational research ranging from device prototyping and animal studies to clinical trial readiness. Disease targets include SARS-CoV-2, tuberculosis, various strains of influenza, African swine fever, and cancer immunotherapy.

Ceres Nanosciences, Inc. is a privately held company based in Northern Virginia, specializing in the development and commercialization of Nanotrap® hydrogel particle technology. Their mission is to deliver innovative products powered by Nanotrap Technology to address life science needs and provide better patient outcomes. Ceres' products enable the capture, concentration, and preservation of low-abundance analytes from diverse biological and environmental samples, supporting applications in diagnostics, research, and public health surveillance. The company is ISO 9001:2015 certified and collaborates with leading research institutions, public health agencies, and industry partners to advance global health security and biosecurity. Ceres has established a national network of Wastewater-based Epidemiology Centers of Excellence and has received significant funding from the NIH RADx initiative and other organizations to expand its impact in underserved communities. Their technology is widely adopted for wastewater-based epidemiology, proteomics, and nucleic acid analysis, with a strong focus on supporting public health monitoring, early detection of infectious diseases, and environmental bio-surveillance.

BrightFocus Foundation is a leading nonprofit organization dedicated to funding innovative scientific research and providing expert information to defeat Alzheimer’s disease, macular degeneration, and glaucoma. With a mission to envision a world where everyone can age free from diseases of mind and sight, BrightFocus invests in groundbreaking research, supports the next generation of scientists, and empowers individuals and families with trusted resources. Over its 50-year history, the foundation has awarded nearly $300 million in research grants to more than 6,000 scientists worldwide, catalyzing life-changing breakthroughs and advancing public education on brain and vision health. The foundation's impact is evident in major scientific milestones, such as the first successful cell transplantation for glaucoma, FDA "Breakthrough Therapy" designations, and the development of new diagnostic and therapeutic approaches for neurodegenerative and vision diseases.

Gel4Med is a commercial-stage company pioneering the use of smart, bioinspired materials to address major challenges in medicine. Founded out of Harvard Innovation Labs, Gel4Med leverages its proprietary Smart Materials Platform™ (SMP™) to develop advanced therapeutics and devices, with a mission to enhance health outcomes and access for all patients. The company is committed to creating novel biomaterials that improve regenerative medicine and surgical solutions, and has achieved significant milestones including FDA clearance for its lead wound care product, G4Derm™ Plus.

Precision Antibody is a leading provider of custom antibody development services, with over 24 years of experience and more than 20,000 successful projects delivered to over 500 organizations worldwide. The company specializes in rapid, high-quality, application-specific monoclonal and polyclonal antibody development, production, and characterization, serving pharmaceutical, biotech, academic, and government clients. Precision Antibody is recognized for its proprietary technologies, award-winning services, and a success rate exceeding 95% in delivering antibodies that perform as intended. Accredited by AAALAC and OLAW, the company is committed to strict quality control, confidentiality, and milestone-based, transparent pricing. Their mission is to enable scientific advancement through innovative, reliable, and tailored antibody solutions.

SERB Pharmaceuticals is a global pharmaceutical group focused on the development, manufacture, and distribution of essential and emergency medicines, including treatments for rare diseases and medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats. Operating across the US, Europe, the Middle East, and Australia, SERB delivers a portfolio encompassing antidotes, biologics, and specialty emergency care products while supporting independent and collaborative research initiatives in critical care and rare disease management.

Instant Systems specializes in the design and manufacture of single-use sterile systems for cell and gene therapy, regenerative medicine, tissue banking, and related bioprocessing applications. The company offers a wide range of customizable solutions for cell culturing, fluid management, media and waste containment, magnetic cell separation, and sterile filtration, with a focus on maintaining process integrity from production through delivery. Their products support closed-system workflows, scalability, and integration into existing manufacturing and research environments.

The Clemson University Research Foundation (CURF) is dedicated to advancing the research enterprise at Clemson University by connecting faculty and students with industry partners. CURF facilitates the commercialization of university technologies, supports research collaboration, and promotes innovation through various funding and support programs.

SynVivo is a pioneering provider of cell-based microfluidic organ-on-chip platforms, delivering biologically realistic microenvironments for real-time study of cellular behavior, drug delivery, and drug discovery. Their proprietary technology bridges microfluidics and bioengineering, enabling advanced research in life sciences, disease modeling, and personalized medicine. SynVivo's chips support microvascular networks that closely mimic in vivo tissue conditions, validated by scientific research to more accurately reflect human biology than conventional culture methods. The platform is especially impactful for personalized cancer therapy, allowing patient-derived cells to be used for drug efficacy testing in a simulated tumor environment. SynVivo also distributes a wide range of high-quality primary cells and cell lines from various species, supporting research in immunology, cardiovascular, and cancer biology.

Hemerus Medical, LLC specializes in designing and developing innovative blood collection, processing, preservation, and storage technologies. Our mission is to improve patient transfusion outcomes and ensure the availability of high-quality, life-saving blood products. Hemerus aims to extend the shelf life of blood products and enhance transfusion safety through advanced technologies like leukocyte reduction filters and novel anticoagulant and additive solutions.

ParaNano Wound Care, LLC is a pre-clinical MedTech company based in Oklahoma City, founded in 2018. The company is dedicated to developing and commercializing advanced wound care solutions, most notably the Bio-Z™ Smart Bandage. ParaNano holds exclusive, worldwide patent rights to foundational nanofiber and biosensor technologies licensed from the University of Central Oklahoma and the University of Manitoba. Their mission is to address the critical gap in wound care by providing real-time, continuous infection detection, empowering both clinicians and patients to intervene early and improve outcomes. ParaNano is recognized for its innovation, strategic partnerships, and commitment to health equity, and is a member of the prestigious Blue Knight program by Johnson & Johnson Innovation and BARDA.

Reliable Systems Engineering, LLC is a consulting firm specializing in systems engineering for the medical device industry. The company supports clients—particularly startups, contract developers, OEMs, and CMOs—through expertise in system architecture, requirements development, risk management, verification, and cross-functional coordination. Its mission is to bring clarity, structure, and guidance to complex device development, ensuring regulatory compliance and efficient progress through disciplined engineering practices, all rooted in recognized industry standards and decades of experience.

Velico® is a private, clinical stage medical technology company headquartered in Beverly, Massachusetts, dedicated to reducing preventable death from bleeding through innovative blood and plasma products. Their flagship product, FrontlineODP™, is a novel dry plasma manufacturing system designed for rapid rehydration and transfusion in emergency settings, aiming to improve patient access to life-saving treatments.

ABOUT The THOR Network Foundation The THOR (Trauma Hemostasis & Oxygenation Research) Network Foundation is a US-based 501(c)(3) public charity organization. It’s members are an international multidisciplinary network of civilian and military providers ranging from first responders and medics to physicians from multiple disciplines, as well as basic scientists, bioengineers, and clinical trialists. The international influence of THOR is evidenced by our membership of over 600 subject matter experts and industry leaders from over 31 countries from 6 continents. OUR MISSION: To develop and implement best practices for prehospital damage control resuscitation in trauma care through to the completion of the acute phase of hemorrhagic shock resuscitation at higher echelons of care. The THOR Network will execute this mission through a multidisciplinary collaborative approach to research, education, training, and advocacy. See www.thornetwork.com for more information about the THOR Network, its foundation, and the Research Institute. The THOR Research Institute (TRI) The THOR Research Institute (TRI), LLC is a subsidiary of the THOR Network Foundation. The purpose of the TRI, LLC is to facilitate medical research to improve patient outcomes in furtherance of Code Section 501(c)(3). The TRI is a Research and Development Institute specializing in translational research and advisory services. It is comprised of investigators that span the translational research pipeline that includes basic science, clinical trials, implementation science. The TRI is unique compared to many other research institutes and consulting groups in that its investigators and advisors are members of a large international multidisciplinary network with a balanced mix of established investigators, and advisors with extensive clinical experience, practical understanding, and knowledge of clinical care required for patients with hemorrhagic shock. THOR and the TRI have demonstrated its ability in performing high quality science challenging long standing dogma in resuscitation medicine that has led to substantial change in practice and improving outcomes globally. The TRI is eligible to submit funding applications for federal funding in the US for projects initiated by TRI investigators. The TRI also collaborates internationally with academia, industry, and federal agencies to perform translational research in the area of resuscitation science to support licensure applications for devices and biologics. While research and development of diagnostics and therapies for trauma-related hemorrhage is our main focus we have an interest in all etiologies of life-threatening bleeding and the use of blood products for resuscitation. TRI Capabilities/Services include the following: 1. Product and Device Development a. Program and Project Management i. Government Contracting Liaison (BARDA, DARPA, DoD) b. Chemistry, Manufacturing, and Controls development c. Right-sized Quality System development d. Pre-clinical program development for products or devices 2. Clinical Research Organization Services a. Clinical study operations for phase 1 through phase 4 trials. i. Trial design ii. Protocol development and operationalization iii. Clinical trial site identification, feasibility, qualification, selection and qualification iv. IRB/ethics and regulatory management b. Clinical program external review 3. Regulatory a. Interface, including correspondence with regulatory authorities as well as authoring and reviewing of pre-IND, IND, NDA, and BLA documentation. b. Experience with global regulatory authorities (TGA, EU, Health Canada, ANVISA) c. CDER, CBER, CDRH 4. Educational a. Development of webinars for educational purposes b. Development of focused scientific symposia 5. Consulting or advisory a. Development of advisory boards for industry, investment firms, and government entities b. Product assessment by end users for practical feedback on military and civilian applications, functionality, and potential for widespread adoption. c. Market analyses, including survey development and dissemination

LSU Health Sciences Center New Orleans is dedicated to educating future health professionals and scientists, advancing research, and providing exceptional healthcare. With six professional schools and numerous affiliated hospitals, LSUHSC-NO aims to improve health outcomes and address health equity challenges in Louisiana.

ORF Biologics, Inc. is a biotechnology company based in Tiffin, Iowa, specializing in the design, development, and manufacturing of advanced biologics for research and therapeutic applications. With over 45 years of industry experience, the company pioneers next-generation biologics, focusing on custom and off-the-shelf solutions for pharmaceutical and biotech companies. ORF Biologics is committed to accelerating scientific discovery through innovative protein engineering, synthetic biology, and rigorous quality control, serving critical fields such as infectious disease, neurodegeneration, regenerative medicine, and biosecurity.

Imbed Biosciences is a privately held medical device company that specializes in the development of advanced devices for the treatment of burns, ulcers, and soft-tissue repair. The company is committed to providing innovative solutions that improve patient care and outcomes through its patented Microlyte® Matrix technology.

Perfusion Medical is dedicated to commercializing PEG-20k, a revolutionary drug designed to treat hemorrhagic shock and other ischemic conditions. With over $18 million in funding from the Department of Defense and numerous studies supporting its efficacy, the company aims to improve patient outcomes significantly.

Applied Research Associates, Inc. (ARA) is a globally recognized scientific research and engineering company dedicated to solving critical national problems to improve safety, security, and quality of life. Founded in 1979, ARA is 100% employee-owned and offers innovative technologies and solutions across various sectors, including national security, infrastructure, health solutions, and energy & environment. The company is committed to delivering mission-critical solutions that exceed expectations and lead to new possibilities.

General Graphene Corporation is a pioneering advanced materials company specializing in the industrial-scale production of chemical vapor deposition (CVD) graphene and carbon materials. Headquartered in Knoxville, Tennessee, the company leverages proprietary, patented roll-to-roll CVD technology to deliver high-quality, reproducible, and affordable graphene and carbon-based materials at mass volumes. Their mission is to make graphene scalable and accessible for real-world applications, enabling innovation across industries such as electronics, energy storage, life sciences, and more. With a focus on overcoming the traditional limitations of CVD graphene manufacturing, General Graphene supports both research and commercial partners in transitioning graphene from laboratory research to industrial adoption, driving the next wave of material science transformation.

Battelle is an independent nonprofit organization dedicated to advancing science and technology to address the world's most pressing challenges. With over 90 years of experience, Battelle transforms knowledge into profound innovation, reinvesting its proceeds into scientific advancement and STEM education. The organization operates across various markets, including health, national security, environment, infrastructure, and industry, providing solutions through limitless innovation and expertise in scientific and engineering disciplines.

Zymo Research is a global biotechnology company specializing in innovative products and services for sample collection, nucleic acid purification, microbiomics, epigenetics, and next-generation sequencing (NGS). With over 30 years of experience, Zymo Research is recognized for simplifying complex scientific workflows and providing reliable solutions for life science research, clinical diagnostics, and molecular biology applications. The company offers a comprehensive portfolio of kits, standards, and services designed to ensure accuracy, reproducibility, and efficiency in molecular analyses, supporting researchers worldwide.

Melio is developing a rapid, culture-free bloodborne pathogen testing platform integrating proprietary assays, microfluidics, and machine-learning. The company targets faster and more accurate infectious disease diagnoses, aiming to reduce antimicrobial misuse and address antibiotic resistance. The platform is designed for comprehensive, direct-from-blood detection of a broad spectrum of pathogens, with a focus on real-time adaptability to new and emerging threats. Melio's system is in development and not yet commercialized.

TechConnect is dedicated to catalyzing innovation for positive change by connecting technologists, entrepreneurs, government leaders, and industry stakeholders. The organization facilitates partnerships and collaboration through events, challenges, and innovation programs, aiming to address critical challenges across various sectors including smart cities, advanced manufacturing, and space technology.

Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.

Northeastern University is a global research university founded in 1898, renowned for its experiential learning model, high-impact research, and deep partnerships. The university emphasizes innovative teaching and research that engage students, faculty, and alumni in solving real-world problems, fostering a dynamic and inclusive community across its 13 campuses worldwide.

Rebel Medicine is a science-led pharmaceutical company dedicated to revolutionizing acute pain management by developing innovative, non-opioid solutions. Their mission is to create impactful products that improve patient outcomes and reduce healthcare costs. By leveraging novel drug delivery technologies, Rebel Medicine aims to provide effective pain management solutions that eliminate the need for opioids, thus addressing a significant unmet medical need in acute and postoperative pain management.

Plas-Free Ltd is a clinical stage HealthTech company specialized in the development and commercialization of vital fluid absorbent devices for blood purification. Founded in 2017, the company focuses on innovative solutions to improve health outcomes and reduce healthcare costs. Their product pipeline aims to address unmet medical needs, particularly in the treatment of massive bleeding and hyperammonemia. The company has demonstrated significant efficacy in reducing bleeding through its ClearPlasma device, which has shown to decrease blood loss by more than 50% in pre-clinical trials.

COMPANY: Founded in 2012, Legacy Innovation Inc is a lean, nimble, technology & product development company inventing technologies in pressure, temperature, and flow (complex fluid dynamics) with corporate headquarters in Boise Idaho and an R&D office at VelocityTX in San Antonio. TEAM: Talented and dedicated entrepreneurs, inventors, engineers, and project managers supported by a diverse collaborative network of subject matter experts and teaming partners across multiple disciplines and market sectors. Teaming Partners tend to have their own IP and know-how to complement Legacy’s innovation. PRIMARY AREAS OF EXPERTISE/COMPETENCIES: Our journey began in the draught beer industry creating award-winning thermoelectric cooling and pressure regulation technologies. During the pandemic, we pivoted those technologies to develop simple, portable, medical device platforms in “bleeding & breathing” specifically designed for prehospital care by EMS / first responders in civilian & military applications, especially effective in austere and remote environments. FULL-SERVICE CAPABILITIES: End-to-end services include concept development, design, rapid prototyping, and manufacturing that leverages subject matter experts and teaming partner organizations for customer discovery, R&D, implementation, and commercialization. Primary R&D activities occur in-house, or in-house at teaming partner facilities, to expedite development. MISSION: Create and deliver targeted solutions in pressure, temperature & flow that disrupt the status quo to create new paradigms and industry standards that give our clients massive competitive advantage with little to no competition. VALUES: 1) Customer Discovery extends far beyond initial investigation to permeate everything we say and do. This delivers maximum value to clients and perpetuates our core technologies. 2) Win/Win Approach ensures that every individual and organization involved in a Legacy project has a definable win other than money to boost engagement and impact. 3) Simple, Elegant, Intuitive Design streamlines commercialization, optimizes user experience, stymies potential competitors, and fast-tracks alternative uses for our technologies. WHAT MAKES US DIFFERENT: While our technical lane is narrow, applications are infinite across a wide range of market sectors from medical to industrial to entertainment. This fosters efficient growth with the diversity to insulate against downturns in the economy and disruption in any one market sector. Our established technology base, focused patent portfolio, and robust niche know-how demonstrate our proven technical acumen. Our military, government, and commercial contracts validate our capacity to meet rigorous standards and deadlines. Our broad and eclectic network spans multiple disciplines and markets including medical, military, government, industrial, and academic sectors. This arms Legacy with a deep well of unique resources and expertise to draw upon for project success. NOTABLE CLIENTS: Apple, ITW, Marriott, US Air Force - 59th Medical Wing, US Department of Transportation (SBIR Phase I & II), National Institute for Defense Health Cooperation / Uniformed Services University (Henry Jackson Foundation contract)

InformedDNA is a leading precision health company dedicated to revolutionizing the application and implementation of genomic insights to enhance patient care and improve outcomes for all. With over 15 years of experience and the largest in-house staff of board-certified genetics specialists in the U.S., InformedDNA combines deep genetics expertise and advanced technology to deliver real-time, evidence-based solutions for optimizing clinical decisions, improving outcomes, and realizing cost savings at scale. The company supports payors, providers, employers, life sciences, and patients with equal access to genomics clinicians, genetic counselors, and tech-driven solutions. InformedDNA is committed to advancing personalized healthcare, health equity, and cost-effective care, shaping the future of precision health through ongoing innovation, education, and a strong focus on integrity and patient privacy.

MaXentric Technologies, founded in 2003, is a leading R&D organization specializing in radio frequency technology and advanced electronics. With over 20 years in the market, MaXentric has developed a robust portfolio of proprietary products and solutions for both commercial and government clients. The company is committed to engineering excellence, innovation, and collaboration, with a highly educated team (over 57% holding advanced degrees) spread across three locations in the US. MaXentric's mission is to deliver high-quality electronics integration, high-end circuitry, and high-speed communication devices, continually pushing the boundaries of next-generation wireless and sensing technologies. The company fosters a diverse, inclusive, and collaborative work culture, offering growth opportunities for employees and interns alike.

Cook MyoSite, a subsidiary of Cook Group, has been advancing human muscle cell technology since 2002. Operating under ISO 9001:2015-certified quality standards, we specialize in primary human skeletal muscle-derived cells and fibro-adipogenic progenitors sourced from healthy donors and individuals with neuromuscular, metabolic, and rare disorders. Our offerings include custom cell procurement, specialized media formulations, and contract manufacturing services—supporting both academic research and clinical development in regenerative medicine. Beyond research tools, Cook MyoSite is pioneering autologous muscle-derived cell therapies. Our investigational product, iltamiocel, is currently in a Phase III clinical trial for fecal incontinence, demonstrating our commitment to translating cell-based science into real-world solutions. With expertise in GMP manufacturing, analytical testing, and tailored partnerships, we empower collaborators to accelerate innovation in musculoskeletal and neuromuscular health worldwide.

Oridivus is pioneering the development of the first FDA-approved oral wound healing therapy, with a mission to transform pediatric oral health outcomes. The company addresses critical unmet needs in oral surgery by accelerating healing, reducing pain, and minimizing opioid dependency, especially in young patients. Oridivus leverages advanced biomaterials and immunomodulatory compounds to provide faster, safer, and more effective recovery for procedures such as wisdom tooth extractions, cleft palate repairs, and oral trauma. Their vision is to improve quality of life for children and young adults, break the cycle of opioid dependency, and set new standards in oral wound care.

Hemanext is a privately held medical technology company specializing in oxygen-controlled red blood cell processing and storage systems for transfusion medicine. The company develops, manufactures, and commercializes innovative storage solutions that preserve the quality and function of red blood cells by limiting oxygen and carbon dioxide exposure, with the goal of improving transfusion outcomes for patients with chronic and acute conditions. Hemanext's products have received FDA De Novo marketing authorization and CE Mark certification, enabling global distribution. The company is recognized for its focus on scientific evidence, operational compatibility, and strategic partnerships with blood establishments and clinical researchers.

SelSym Biotech is dedicated to developing innovative therapeutics to address critical clinical needs in hemorrhage control, surgical bleeding, and wound healing. Their mission is to transform patient care and outcomes through advanced technologies like their Hemostatic Healing Hydrogels and SymClot, a novel therapy that mimics platelet functions to enhance hemorrhage control and address platelet supply shortages.

Luna Labs is a world-class technology and product development resource for the defense and healthcare industries. Collaborating across our core capabilities in Advanced Materials, Engineered Systems, and Biotechnology, our teams generate solutions for the most demanding environments and customers to save time, save money, and save lives. We partner with universities, government labs, and other world class companies to explore technological feasibility of new ideas, align technologies with customer needs, and generate solutions. Working with a robust global network of manufacturers, suppliers, licensees, and distributors, Luna Labs develops everything from small-scale prototypes up to market-ready products.

Tunnell Government Services, Inc. is a subsidiary of Tunnell Consulting, Inc., dedicated to providing professional services to government agencies. The company focuses on transforming organizations to achieve sustainable results and fulfill agency missions. With expertise in public health preparedness, biodefense lab support, and scientific project portfolio management, Tunnell Government Services partners with government organizations to address the greatest threats to public health and enhance organizational performance.

Pressure Medical develops advanced medical devices focused on severe hemorrhage control and trauma care, particularly for military and high-risk civilian environments. The company specializes in smart pneumatic and junctional tourniquets designed for rapid and effective bleeding control in emergency situations, emphasizing ease of use, minimal training requirements, and patient limb preservation. With multiple issued patents and collaborations with government and defense agencies, Pressure Medical aims to enhance combat medical care and improve survival outcomes through innovative biomedical engineering.

Corscience is a German-based medical technology development and manufacturing provider specializing in advanced solutions for defibrillation, patient monitoring, and vital sign acquisition. The company supports OEMs and medtech startups internationally with expertise across R&D, regulatory affairs (including MDR and FDA compliance), quality management, lifecycle management, and technical consulting. Their track record includes the delivery of complex, safety-critical systems and robust integration of electronic, software, and mechanical components in medical devices.

Epicore Biosystems is a digital health company specializing in biowearables for non-invasive monitoring of hydration, metabolic health, and stress through sweat analysis. Their solutions support industrial workers, athletes, and clinical researchers by converting sweat biomarkers and physiological data into actionable insights for real-time health, safety, and performance management. The company combines expertise in data science, material science, and biomedical engineering to create validated, user-centric wearable technologies, and partners with organizations across healthcare, academia, industry, and public health sectors.

The Office of Sponsored Programs (OSP) at Georgia Tech provides comprehensive support for research administration, including proposal preparation, contract negotiation, and compliance with federal and state regulations. OSP aims to facilitate research by offering educational resources, guidance, and administrative support to faculty and research administrators throughout the award lifecycle. Additionally, OSP is committed to improving and modernizing contract management processes, ensuring compliance with various agreements, and fostering collaborative research efforts.

Rx Bandz is dedicated to developing innovative, next-generation auto-injectors and life-saving formulations that provide simple solutions for patients, first responders, and the military. Their mission is to enhance the delivery of injectable medications, ensuring accessibility and ease of use for anyone, anytime, anywhere.

Athena GTX is dedicated to advancing wireless, mobile, patient-worn monitoring solutions for both military and civilian markets. The company focuses on connecting patients and providers through state-of-the-art medical and communication technology, developed and produced in Iowa. Athena GTX aims to enhance patient outcomes by integrating innovative wireless technology with reliable devices, supporting first responders and medical professionals in various challenging environments.

Prytime Medical Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control, particularly through the use of the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) technique. The company aims to improve survival rates in trauma situations where hemorrhage is the leading cause of potentially survivable death. Prytime is committed to revolutionizing the care of severely injured patients by enabling trauma teams to gain control of life-threatening bleeding as a bridge to definitive repair.

Partner Therapeutics, Inc. (PTx) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer and other serious diseases. With a strong foundation in oncology, PTx also leads research in infectious diseases, immunology, and urgent clinical needs such as COVID-19 and sepsis. The company integrates research, manufacturing, development, and commercialization to rapidly bring therapies to patients worldwide, emphasizing collaboration with medical and scientific communities to improve patient outcomes and quality of life. PTx's mission-driven approach is supported by a leadership team with deep industry experience and a commitment to advancing late-stage therapeutics that address significant unmet medical needs. The company also maintains a robust compliance program in accordance with state and federal regulations.

Sciperio Inc. is a pioneering research and development company at the forefront of physical and biological innovation. With a transdisciplinary engineering approach, Sciperio excels in mechanical, chemical, electrical, and biological sciences, pushing the boundaries of traditional scientific fields to develop next-generation technologies. The company is committed to advancing technology for the betterment of humankind, with core capabilities in additively manufactured electronics, mechatronics, machine learning, printed electronics, and biological engineering. Sciperio's mission is to research new concepts and develop technologies that connect people, mobilize businesses, and enhance life through advanced technology.

Mantel Technologies is dedicated to closing capability gaps through innovative product development and expert technical services. The company emphasizes collaboration with customers, partners, and end users to deliver impactful solutions across various industries, including material systems, veterinary technology, energy and power solutions, and technology discovery.

Biobeat is a global leader in wearable remote patient monitoring technology, revolutionizing hypertension diagnosis and management through innovative, non-invasive, cuff-less blood pressure monitoring systems. Their mission is to ensure all hypertension patients are monitored and managed effectively, empowering healthcare providers with accurate, real-time data to optimize patient care. Biobeat leverages proprietary patented PPG sensor technology and advanced data analytics to deliver continuous, medical-grade monitoring solutions that enhance clinical decision-making, improve patient compliance, and enable proactive interventions. With FDA-cleared and CE-certified devices, Biobeat is committed to transforming healthcare delivery, supporting both in-hospital and home-based care, and driving better patient outcomes worldwide.

MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Their mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. They offer programs and resources to support innovators in the medtech industry, including webinars, fellowships, and strategic partnerships.

Founded in 2018 in Baltimore, BC3 Technologies is a minority-owned enterprise dedicated to revolutionizing emergency medical response. The company focuses on addressing critical gaps in emergency medical care, particularly in the management of life-threatening arterial bleeding, through innovative hemostatic solutions. BC3 Technologies aims to save lives by providing efficient, effective, and accessible products for medical, military, and general consumer sectors.

KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.

ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.

Inertia is an innovation-driven firm delivering end-to-end design, engineering, prototyping, and manufacturing for medical, clean tech, industrial, safety, and advanced hardware industries. Distinguished by their tightly integrated evidence-based approach—including strategy, human factors, regulatory and advanced manufacturing—they execute at every phase: from early startup product validation through SMB innovation acceleration, to full-scale manufacturing for startup and large enterprises. Their unique differentiator lies in the seamless integration of product strategy, development, and manufacturing under one roof—enabling clients to optimize quality, achieve rapid speed-to-market, and realize measurable cost and risk reductions. With robust quality systems, client-centered project management, and a reputation for transparency, Inertia consistently sets new standards for product innovation and commercialization.

The Geneva Foundation is a 501(c)3 nonprofit established in 1993, dedicated to advancing military medicine through research, development, and education. With a commitment to ensuring optimal health for service members and the communities they serve, Geneva collaborates with various partners to drive innovative medical research and improve healthcare outcomes.

ClotProtect Therapeutics Limited is a UK-based therapeutics spin-out from the University of Leeds, pioneering a first-in-class small molecule anti-fibrinolytic to address acute bleeding. The company is led by a team of world-leading scientific experts, clinical key opinion leaders, and experienced pharma industry professionals. Their mission is to transform the treatment of acute haemorrhage and traumatic bleeding, aiming to save lives with innovative, more effective therapies. ClotProtect is currently in preclinical development, working towards identifying a clinical drug candidate that offers superior efficacy and safety compared to current standards of care.

Tensentric is a contract design and manufacturing firm focused solely on medical device, in vitro diagnostic, and advanced therapy markets. We're ISO13485 certified and FDA registered to help our clients bring their new technology and products to market.

SIENI Holdings is a pioneering biotech company focused on developing localized therapies for the treatment of musculoskeletal conditions, including inflammation, infection, pain, and the prevention of post-surgical complications. Their mission is to enable faster healing and safer recovery by minimizing systemic drug exposure through their innovative AEGEAL platform, which delivers FDA-approved drugs directly to the site of injury or surgery. SIENI's vision is to provide versatile, precise, and bioresponsive solutions adaptable across orthopedic, trauma, burn, and veterinary applications, addressing a significant global health burden and market opportunity.

The Icahn School of Medicine at Mount Sinai, located in New York City, is an international leader in biomedical education, research, and patient care. As the academic partner of the Mount Sinai Health System, the school is renowned for its innovative education, groundbreaking research, and commitment to health equity. With over 7,000 faculty, 1,200 students, and 2,500 residents and fellows, the institution fosters a culture of bold thinking, multidisciplinary teamwork, and a willingness to challenge conventional wisdom. Its mission is to radically advance the art and science of medical care through collaborative learning, scholarly inquiry, and a deep respect for diversity, preparing the next generation of healthcare leaders to revolutionize medicine and biomedical science.

Zymeron is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative healthcare technologies that deliver step-change performance. The company focuses on proactive health solutions to address critical unmet needs in the pharmaceutical sciences, particularly in drug delivery and formulation technologies.

Omniox is an IND-stage biotherapeutics company focused on developing innovative H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles. These biologics are designed to safely deliver oxygen to hypoxic tissues, addressing significant unmet medical needs and improving patient outcomes.

Signature Science, LLC is a multidisciplinary applied science and technology company dedicated to solving the toughest forensic, biosecurity, and public health challenges. Serving both government and commercial clients, Signature Science combines scientific rigor with proven quality assurance to enhance the credibility and defensibility of programs in national security, public safety, and health security. The company is recognized for its innovation, technical excellence, and commitment to advancing the state-of-the-art in forensic science, genomics, and biosecurity technologies. Signature Science also offers advanced bioinformatics and microbiome analysis services, empowering clients with data-driven insights to address emerging threats, pandemics, and bioterrorism. The company is a subsidiary of Southwest Research Institute and is committed to community engagement and workforce development.

Scopemed focuses on innovative respiratory care by developing modular, multifunctional oxygen delivery devices. The company's mission is to leverage clinical innovation to create advanced respiratory solutions capable of high flow oxygen therapy, positive pressure support, and passive oxygen delivery. Scopemed products aim to enhance safety in medical procedures, reduce respiratory particle transmission, and provide adaptable oxygen therapy across various clinical environments.

The Coalition for National Trauma Research (CNTR) is dedicated to saving lives and reducing disability through trauma research. Their mission focuses on coordinating research efforts, strengthening infrastructure for multi-center investigations, and advocating for sustainable research funding to address the burden of traumatic injuries.

The Center for Military Medicine Research (CMMR) at the University of Pittsburgh is dedicated to advancing medical research for wounded service members and their families. The center focuses on trauma, emergency, and critical care, leveraging the university's strengths in medical and engineering fields, and collaborating with Carnegie Mellon University's robotics and AI expertise. CMMR aims to enhance trauma care for warfighters and civilians, contributing to the defense innovation economy.